Full Breakdown
New York Establishes First Statewide Frontotemporal Degeneration Research Registry
10/22/2025, 9:09:18 PM
Overview of the Legislation
New York State has become the first in the United States to establish a statewide research registry for Frontotemporal Degeneration (FTD), a form of dementia. This initiative, spearheaded by State Senator Michelle Hinchey and Assemblymember Amy Paulin, was signed into law by Governor Kathy Hochul. The legislation, identified as bill S.598B/A.1985C, received unanimous support from both legislative houses during the 2025 session.
Purpose and Function of the Registry
The New York State Frontotemporal Degeneration Research Registry aims to track FTD diagnoses, enhance awareness within the medical community, and ultimately contribute to finding a cure for the disease. The registry will require hospitals and healthcare providers to report FTD cases to the New York State Department of Health (DOH), which will create an online portal for public access to data on the incidence and prevalence of FTD.
Key Figures and Their Perspectives
Senator Michelle Hinchey emphasized the personal motivation behind the legislation, stating, “New York is now the first state in the country to establish a Frontotemporal Degeneration (FTD) Research Registry—a law inspired by my father’s battle with FTD.” She highlighted the importance of understanding the disease's scale in New York and addressing healthcare gaps that hinder timely diagnosis and care.
Assemblymember Amy Paulin, Chair of the Assembly Health Committee, noted that FTD is the most common form of dementia in individuals under 60. She expressed pride in collaborating with Hinchey and thanked Governor Hochul for her support in advancing care and research for FTD.
Emma Heming Willis, an advocate for FTD awareness, remarked, “This registry makes New York the nation's leader in fighting FTD,” underscoring the significance of accurate diagnosis data in the quest for treatments and cures.
Implications for Families and Healthcare
The establishment of the FTD Research Registry is expected to facilitate faster and more accurate diagnoses, which are crucial given that FTD often takes nearly four years to diagnose due to symptom misinterpretation. The financial burden of FTD on families is substantial, with costs nearly double those associated with Alzheimer’s disease. The registry aims to alleviate some of these challenges by improving care and support for affected families.
Meghan Buzby, Director of Advocacy and Volunteer Engagement at the Association for Frontotemporal Degeneration (AFTD), stated that the data collected will be essential for advocating increased public investment in caregiving and research resources.
Conclusion
The creation of the Frontotemporal Degeneration Research Registry in New York represents a significant step forward in understanding and addressing FTD. By tracking diagnoses and raising awareness, the initiative aims to improve care for patients and families while setting a precedent for similar efforts across the country.
